← Back to Search
Targeting Liver Cancer Via ASGP Receptor Using 5-FU-loaded Surface-modified PLGA Nanoparticles
Ruchi Dangi, P. Hurkat, Ankit Jain, Satish Shilpi, A. Jain, A. Gulbake, S. Jain
Published 2014 · Materials Science, Medicine
Download PDFAnalyze on Scholarcy
Abstract Context: Liver cancer is widespread liver malignancy in the world, for an estimated one million deaths annually. Objective: In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma. Materials and methods: Lactobionic acid conjugated PLGA was used to prepare LDNPs using modified emulsion diffusion method. Results: They were characterised for particle morphology, particle size (below 150 nm), zeta potential and polydispersity index (PDI ∼0.35), entrapment efficiency (∼60.23%), and cumulative percent drug release. Discussion: LDNPs in ex-vivo cell line studies on human cancer cell line HepG2 exhibited significantly higher cytotoxicity compared to 5-FU and DNPs (unconjugated PLGA NPs) with growth inhibition 50% (GI50) of 66.7 µg/mL, 50.2 µg/mL and 35.5 µg/mL, respectively. In vivo studies exhibited higher drug concentration about 37.52 ± 0.68% in liver as compared to other organs and plasma. Conclusion: Thus, LDNPs showed high drug loading, specificity, biocompatibility and efficacy in treatment of liver cancer.
This paper references
Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy
S. De (2008)
Surgery and ablative therapy for hepatocellular carcinoma.
C. Cha (2002)
ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript Profile
Rebecca Harris (2012)
UK cancer incidence statistics by age
Cancer Research UK. (2007)
Lokal ablative Therapien des hepatozellulären Karzinoms
J. Sturm (2001)
Receptor-mediated endocytosis and targeted drug
RJ Fallon (1985)
The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents
C. Gavegnano (2012)
5-Fluorouracil-loaded PLA/PLGA PEG–PPG–PEG polymeric nanoparticles: formulation, in vitro characterization and cell culture studies
Harika Öcal (2014)
[Locally ablative therapies of hepatocellular carcinoma].
J. Sturm (2001)
Hepatocellular carcinoma--cause, treatment and metastasis.
Z. Tang (2001)
Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics.
H. Jeon (2000)
Development of a novel probe sonication assisted enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for magnetic targeted drug delivery system.
R. K. Dutta (2012)
New colorimetric cytotoxicity assay for anticancer-drug screening.
Philip Skehan (1990)
The effect of type of organic phase solvents on the particle size of poly(d,l-lactide-co-glycolide) nanoparticles
K. Song (2006)
5-Fluorouracil-loaded Self-assembled pH-sensitive Nanoparticles as Novel Drug Carrier for Treatment of Malignant Tumors
L. Liu (2006)
Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases
L. Li (2010)
5-Fluorouracilloaded PLA/PLGA PEG–PPG–PEG polymeric nanoparticles: Formulation, in vitro characterization and cell culture studies
K Goracinova (2013)
Carbohydrate-specific receptors of the liver.
G. Ashwell (1982)
Preparation and characterisation of 5–fluorouracil containing PLGA nanospheres coated with chitosan, for drug delivery
A. Calderini (2012)
Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety.
I. Kim (2003)
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C. Verslype (2012)
Galactosylated Chitosan Oligosaccharide Nanoparticles for Hepatocellular Carcinoma Cell-Targeted Delivery of Adenosine Triphosphate
Xiu Liang Zhu (2013)
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
R. Dinarvand (2011)
Rapid separation of low molecular weight solutes from liposomes without dilution.
D. Fry (1978)
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
R. Aravalli (2013)
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
J. Park (2009)
Sulforhodamine B colorimetric assay for cytotoxicity screening
V. Vichai (2006)
Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors
W. Sun (2013)
Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Hsiang-Fa Liang (2006)
Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres cotaining bodipy
D Sinjan (2004)
Transcatheter arterial chemoembolization for hepatocellular carcinoma
Chien-Fang Yang (2004)
Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration.
P. Ahlin (2002)
Hepatocellular Carcinoma: An Asian Perspective
E. K. Teo (2001)
Characterization of the asialoglycoprotein receptor in a continuous hepatoma line.
A. Schwartz (1981)
N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.
S. Medina (2011)
Nondestructive and on-line monitoring of tablets using light-induced fluorescence technology
C. K. Lai (2008)
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Xiaoju Zhou (2012)
An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield.
M. Nassim (2002)
Receptor‐mediated endocytosis and targeted drug delivery
R. Fallon (1985)
The asialoglycoprotein receptor internalizes and recycles independently of the transferrin and insulin receptors
A. Ciechanover (1983)
Cancer Research UK
E. Wilkinson (2002)
This paper is referenced by
Running head: REVIEW OF POLYMETHYL-METHACRYLATE COPOLYMERS 1 Research and Review of Polymethyl-methacrylate Copolymers in the Development of Enhanced Pharmaceutical Delivery Systems
Jacob A. Dyess (2020)
Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
U. Ruman (2020)
Killing effect of 5-fluorouracil loaded polycaprolactone nanoparticles on human cholangiocarcinoma cells in vitro
Li Yong-sheng (2015)
Longitudinal assessment of ultrasound‐guided complementary microRNA therapy of hepatocellular carcinoma
Sayan Mullick Chowdhury (2018)
Thermal properties and morphology changes in degradation process of poly(L-lactide-co-glycolide) matrices with risperidone.
A. Turek (2015)
Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis
A. Verma (2019)
Ligand-directed stearic acid grafted chitosan micelles to increase therapeutic efficacy in hepatic cancer.
Y. Yang (2015)
Improving chemotherapy drug delivery by nanoprecision tools
Nehal A. Salahuddin (2017)
LC-MS/MS Determination of Lactobionic Acid: Application to Assessment of Nanoparticle Functionalization
F. Farouk (2020)
Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
M. El-Hammadi (2017)
Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance
R. Rohilla (2016)
Advances in liposomal drug delivery to cancer: An overview
Shivani Saraf (2020)
Nanotheranostics: Their role in hepatocellular carcinoma.
Rama Rao Malla (2020)
Eudragit S100 Coated Citrus Pectin Nanoparticles for Colon Targeting of 5-Fluorouracil
M. Subudhi (2015)